NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:NK
- CUSIP: N/A
- Web: www.nantkwest.com
Capitalization:- Market Cap: $585.77 million
- Outstanding Shares: 82,155,000
Average Prices:- 50 Day Moving Avg: $6.41
- 200 Day Moving Avg: $4.86
- 52 Week Range: $2.71 - $9.60
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.92
- P/E Growth: 3.35
Sales & Book Value:- Annual Revenue: $48,999.00
- Price / Sales: 11,954.63
- Book Value: $3.39 per share
- Price / Book: 2.10
Profitability:- EBIDTA: ($114,060,000.00)
- Net Margins: -233,973.47%
- Return on Equity: -37.90%
- Return on Assets: -35.37%
Debt:- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 13.80%
- Quick Ratio: 13.80%
Misc:- Average Volume: 670,789 shs.
- Beta: 3.65
- Short Ratio: 6.04
Frequently Asked Questions for NantKwest (NASDAQ:NK)
What is NantKwest's stock symbol?
NantKwest trades on the NASDAQ under the ticker symbol "NK."
How were NantKwest's earnings last quarter?
NantKwest, Inc. (NASDAQ:NK) released its quarterly earnings results on Monday, August, 15th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.06. The business earned $0.01 million during the quarter, compared to analyst estimates of $0.10 million. NantKwest had a negative net margin of 233,973.47% and a negative return on equity of 37.90%. View NantKwest's Earnings History.
Where is NantKwest's stock going? Where will NantKwest's stock price be in 2017?
5 brokerages have issued twelve-month price targets for NantKwest's shares. Their predictions range from $3.00 to $23.00. On average, they expect NantKwest's share price to reach $11.40 in the next year. View Analyst Ratings for NantKwest.
What are analysts saying about NantKwest stock?
Here are some recent quotes from research analysts about NantKwest stock:
- 1. According to Zacks Investment Research, "NantKwest, Inc. is a clinical-stage immunotherapy company. The Company's product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. " (7/12/2017)
- 2. Jefferies Group LLC analysts commented, "Following recent development updates, we have adjusted our model to reflect increased risks, delayed timelines and reprioritization of certain programs. We view NK shares as fairly valued and see no meaningful catalysts for NK over the next 12-18 month period. We downgrade to Hold with a new PT of $6." (1/24/2017)
Who are some of NantKwest's key competitors?
Some companies that are related to NantKwest include Amarin Corporation PLC (AMRN), Xencor (XNCR), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP), Omeros Corporation (OMER), Acorda Therapeutics (ACOR), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Ascendis Pharma A/S (ASND), PTC Therapeutics (PTCT), NeuroDerm (NDRM), ZIOPHARM Oncology (ZIOP), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), Keryx Biopharmaceuticals (KERX), Achaogen (AKAO) and Epizyme (EPZM).
Who are NantKwest's key executives?
NantKwest's management team includes the folowing people:
- Patrick Soon-Shiong M.D., Chairman of the Board, Chief Executive Officer
- Barry J. Simon M.D., President, Chief Operating Officer, Director
- Steven Gorlin, Vice Chairman of the Board
- Richard J. Tajak, Interim Chief Financial Officer
- Michael D. Blaszyk, Independent Director
- Richard P. Kusserow, Independent Director
- John T. Potts Jr. M.D., Independent Director
- John C. Thomas Jr., Independent Director
When did NantKwest IPO?
(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.
Who owns NantKwest stock?
NantKwest's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Asset Dedication LLC (0.02%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own NantKwest stock include Angela Wilson, Barry J Simon, John C Thomas and Steve Gorlin. View Institutional Ownership Trends for NantKwest.
Who bought NantKwest stock? Who is buying NantKwest stock?
How do I buy NantKwest stock?
Shares of NantKwest can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NantKwest's stock price today?
One share of NantKwest stock can currently be purchased for approximately $7.13.
MarketBeat Community Rating for NantKwest (NASDAQ NK)MarketBeat's community ratings are surveys of what our community members think about NantKwest and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for NantKwest (NASDAQ:NK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.40) |
| Consensus Price Target: | $11.40 (59.89% upside) |
Analysts' Ratings History for NantKwest (NASDAQ:NK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/15/2017 | Citigroup Inc. | Downgrade | Neutral -> Sell | $3.00 | High |  |
| 5/8/2017 | Jefferies Group LLC | Set Price Target | Hold | $4.00 | Medium | |
| 3/17/2017 | FBR & Co | Reiterated Rating | Outperform -> Outperform | $22.00 -> $9.00 | Low | |
| 8/19/2016 | Canaccord Genuity | Reiterated Rating | Buy | $18.00 | N/A | |
| 8/17/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $32.00 -> $23.00 | N/A | |
| 6/2/2016 | Raymond James Financial, Inc. | Initiated Coverage | Market Perform | | N/A | |
| 8/24/2015 | MLV & Co. | Initiated Coverage | Buy | $35.00 | N/A | |
(Data available from 7/23/2015 forward)
Earnings History for NantKwest (NASDAQ:NK)Earnings History by Quarter for NantKwest (NASDAQ NK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/15/2016 | Q2 | ($0.35) | ($0.41) | $0.10 million | $0.01 million | View | N/A | |
| 5/16/2016 | Q1 | ($0.24) | ($0.38) | $0.10 million | $0.01 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for NantKwest (NASDAQ:NK)Current Year EPS Consensus Estimate: $-1.27 EPS
Next Year EPS Consensus Estimate: $-1.45 EPS
Dividend History for NantKwest (NASDAQ:NK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NantKwest (NASDAQ:NK)Insider Ownership Percentage: 70.19%
Institutional Ownership Percentage: 19.79%
Insider Trades by Quarter for NantKwest (NASDAQ:NK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/20/2017 | Steve Gorlin | Director | Sell | 40,000 | $7.78 | $311,200.00 | |
| 11/25/2016 | John C Thomas | Director | Sell | 6,168 | $7.50 | $46,260.00 | |
| 11/23/2016 | John C Thomas | Director | Sell | 20,000 | $7.50 | $150,000.00 | |
| 9/8/2016 | Barry J Simon | Insider | Sell | 32,000 | $7.49 | $239,680.00 | |
| 12/10/2015 | Angela Wilson | CFO | Buy | 3,265 | $15.33 | $50,052.45 | |
| 8/21/2015 | Steve Gorlin | Director | Sell | 450,000 | $23.00 | $10,350,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for NantKwest (NASDAQ:NK)
Latest Headlines for NantKwest (NASDAQ:NK)
| Source: |
|
| Date | Headline |
|---|
 | Haeggquist & Eck, LLP Investigates NantKwest Inc. for Potential Breaches of Fiduciary Duty by Its Board of Directors - Business Wire (press release)
www.businesswire.com - July 16 at 1:27 PM |
 | Haeggquist & Eck, LLP Investigates NantKwest Inc. for Potential Breaches of Fiduciary Duty by Its Board of Directors
finance.yahoo.com - July 15 at 6:52 AM |
 | Analysts Forecast 10% Upside For The Holdings of IWN
www.nasdaq.com - July 8 at 1:01 PM |
 | NantKwest, Inc. (NK) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 3 at 9:15 AM |
| NantKwest, Inc. (NK) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - June 24 at 12:36 PM |
| NantKwest, Inc. (NK) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - June 24 at 7:08 AM |
| Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago
finance.yahoo.com - June 21 at 8:02 PM |
| Steve Gorlin Sells 40,000 Shares of NantKwest, Inc. (NK) Stock
www.americanbankingnews.com - June 21 at 7:46 PM |
| ETFs with exposure to NantKwest, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 5:55 PM |
| NantKwest (NK) Looks Good: Stock Moves Up 8.5% in Session ... - Nasdaq
www.nasdaq.com - June 17 at 6:03 AM |
| NantKwest (NK) Looks Good: Stock Moves Up 8.5% in Session
finance.yahoo.com - June 16 at 7:48 PM |
| NantKwest, Inc. (NK) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - June 15 at 12:44 AM |
| 2 Longs And 2 Shorts To Watch
finance.yahoo.com - June 14 at 10:49 PM |
 | BRIEF-NantKwest expands nant cancer vaccine program
www.reuters.com - June 7 at 11:37 PM |
| NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease
finance.yahoo.com - June 6 at 9:01 AM |
| Nantkwest Inc (NK) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 6 at 7:20 AM |
| Reviewing Bioverativ (BIVV) & Nantkwest (NK)
www.americanbankingnews.com - June 5 at 8:00 AM |
| NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017 - Business Wire (press release)
www.businesswire.com - June 3 at 1:17 AM |
| NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017
finance.yahoo.com - June 2 at 8:15 PM |
| Zacks Investment Research Lowers Nantkwest Inc (NK) to Hold
www.americanbankingnews.com - May 30 at 8:56 PM |
| Biotech Movers: Cerus, Alexion, NantKwest
finance.yahoo.com - May 23 at 10:13 AM |
| NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs - Business Wire (press release)
www.businesswire.com - May 18 at 8:09 AM |
| NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs
finance.yahoo.com - May 18 at 8:09 AM |
| NantKwest to Present at 2017 Bank of America Merrill Lynch Healthcare Conference
finance.yahoo.com - May 16 at 10:15 AM |
| NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology
finance.yahoo.com - May 16 at 10:15 AM |
| Nantkwest Inc (NK) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 16 at 7:32 AM |
| ETFs with exposure to NantKwest, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 6:08 PM |
| Nantkwest Inc (NK) Lowered to Sell at Citigroup Inc
www.americanbankingnews.com - May 15 at 5:42 PM |
| NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : May 15, 2017
finance.yahoo.com - May 15 at 10:10 AM |
| Short Interest in Nantkwest Inc (NK) Decreases By 20.6%
www.americanbankingnews.com - May 14 at 8:44 AM |
| Nantkwest Inc (NK) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 13 at 9:40 AM |
| Nantkwest Inc (NK) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 12 at 7:40 AM |
| NantKwest, Inc. :NK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 12:04 PM |
| NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with ...
www.businesswire.com - May 9 at 6:28 PM |
| Nantkwest Inc (NK) PT Set at $4.00 by Jefferies Group LLC
www.americanbankingnews.com - May 9 at 2:34 PM |
 | NantKwest (NK) and NantCell Announce FDA Authorization for NANT Cancer Vaccine Clinical Trials
www.streetinsider.com - May 9 at 11:32 AM |
| NantKwest reports 1Q loss
finance.yahoo.com - May 9 at 11:31 AM |
| NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer
finance.yahoo.com - May 9 at 11:31 AM |
| Nantkwest (NK) Receives Media Impact Score of 0.25
www.americanbankingnews.com - May 5 at 10:34 PM |
| ETFs with exposure to NantKwest, Inc. : May 4, 2017
finance.yahoo.com - May 4 at 6:53 PM |
| Court denies NantKwest bid to patent 'promising' cancer treatment
www.reuters.com - May 3 at 10:51 PM |
| Nantkwest (NK) Receives Media Sentiment Rating of -0.22
www.americanbankingnews.com - May 2 at 1:52 PM |
| Nantkwest (NK) Getting Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 28 at 12:26 AM |
| ETFs with exposure to NantKwest, Inc. : April 24, 2017
finance.yahoo.com - April 24 at 6:25 PM |
| Zacks: Brokerages Expect Nantkwest Inc (NK) to Post -$0.37 Earnings Per Share
www.americanbankingnews.com - April 24 at 2:34 PM |
| Nantkwest (NK) Receives Daily Media Impact Score of -0.11
www.americanbankingnews.com - April 23 at 3:13 PM |
| Nantkwest (NK) Getting Positive Press Coverage, Study Finds
www.americanbankingnews.com - April 20 at 4:26 PM |
| Nantkwest Inc (NK) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 17 at 10:14 AM |
| Nantkwest (NK) Getting Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 16 at 1:25 PM |
| ETFs with exposure to NantKwest, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 7:15 PM |
NantKwest (NK) Chart for Sunday, July, 23, 2017
